Growing collaboration with New York Kidney & Hypertension Medicine
Renalytix collaborates with NYKHM to bring kidneyintelX.dkd testing to underserved communities in the Greater New York area, enabling access for over 2,000 patients.
Medicare Issues Final Coverage Determination for kidneyintelX.dkd
Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage
KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
Guidelines highlight the importance of risk prediction and personalized treatment to reduce risk
Update on kidneyIntelX.dkd Local Coverage Determination Consideration
Local Coverage Determination would result in contracted coverage for an estimated additional five million Medicare patients with Type 2 diabetes and early-stage chronic kidney disease
US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix
US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix
Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd
World leading, multi-disciplinary experts advise on adoption of FDA authorized KidneyintelX.dkd across 14 million US patients with diabetes and chronic kidney disease
Renalytix Announces Middle East Distribution Agreement with Vector Pharma
Distribution agreement opens kidneyintelX.dkd testing to address early-stage kidney disease in region with one of the highest incidence rates for type 2 diabetes globally
Renalytix announces a c.$20.3 million private placement
Renalytix announces a c.$20.3 million private placement
Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United States
Award for consortium of industry, academic and clinical research leaders to develop personalized drug response tests in chronic kidney disease
Renalytix Completes Agreement with Veterans Administration to Integrate KidneyIntelX Testing across all Electronic Health Record systems
Significant milestone will make KidneyIntelX accessible to 960,000 veterans with chronic kidney disease
Renalytix Reports Full Year Fiscal 2022 Results
Renalytix announced its full year results for the twelve months ended 30 June 2022.
KidneyIntelX Medicare Update
Renalytix announced that the Federal Medicare Administrative Contractor (MAC) National Government Services (NGS) has initiated payment of claims for KidneyIntelX testing for patients with Medicare coverage.
